For patients with rectal cancer, no biomarker capable of improving monitoring and selection exists for those managed with a watch-and-wait (W&W) strategy, notes Franck Pagès, MD, PhD. Following neoadjuvant chemoradiotherapy,...
Read More
Cancer survivors have a significantly higher prevalence of hearing loss (HL) than the general...
Read More
Many cancer centers are still experiencing a shortage of carboplatin, cisplatin, and other...
Read More
From 2004 to 2020, there was an increase in the use of shorter radiotherapy (RT) courses...
Read More
Multicancer early detection (MCED) blood tests are feasible for detecting cancer, according to a...
Read More
